News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Pulmatrix Announces Presentations at European Respiratory Society Annual Congress for Lead Inhaled iCALM Drug Candidate, PUR118


8/27/2012 10:13:24 AM

LEXINGTON, Mass.--(BUSINESS WIRE)--Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, announced today that three posters on its lead iCALM™ therapeutic, the first treatment developed utilizing its iSPERSE™ inhaled drug platform, will be presented at the European Respiratory Society (ERS) Annual Congress taking place September 1-5, 2012, in Vienna, Austria.

Read at BioSpace.com


comments powered by Disqus
Pulmatrix
 
 

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES